跳至主要内容
临床试验/NCT01295099
NCT01295099撤回4 期

Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease

Queen Mary University of London1 个研究点 分布在 1 个国家开始时间: 2011年2月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
试验地点
1
主要终点
Keloid Scar Reduction

研究概览

简要总结

To clarify the mechanisms of Keloid scar formation.

Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment

Identify the genetic link with Keloid scar formation.

Quantify the psychological/social impact in keloid scarring patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult ( > 18 years old).
  • Keloid scarring present.
  • Able to understand and give informed consent.
  • Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty).
  • Patients with a strong familial pedigree of keloid scar formation.

排除标准

  • Open wound at or proximity of the lesion
  • Infected lesion
  • Pregnant or planning pregnancy in the near future
  • Lactating (Breast Feeding)
  • Abnormal renal or liver function tests
  • Atrophic scars
  • Patient under 18 years of age
  • Immunocompromised
  • OR immunosuppressed

研究组 & 干预措施

5-Fluorouracil

Active Comparator

Patients with small keloidal scars to have intralesional 5FU injected

干预措施: 5- fluorouracil (Drug)

Radiotherapy

Active Comparator

Large keloid scars undergo extralesional excision and radiotherapy

干预措施: radiotherapy (Radiation)

TAC

Active Comparator

干预措施: Triamcinolone (Drug)

结局指标

主要结局

Keloid Scar Reduction

时间窗: 18 months

Using a 3D scanner to observe the reduction of the scar volume measured in cubic centimetres

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验